1. Amarin Corporation (NASDAQ:AMRN) popped a couple days ago with a wedge and has been up five days in a row, gaining, on Wednesday, another 1.15, or 5.32%, to 22.78, with a high of 22.98, on nearly 11 million shares. But, more importantly, it went through a little gap and is up against resistance. I have a target of 24-24 1/2. If it can get through that, it might have a shot at 27.
2. Bed Bath & Beyond (NASDAQ:BBBY) popped 81 cents, or 6%, to 14.81, with a high of 14.88, on 3.8 million shares on Wednesday. That was a nice comeback and solid up day. It closed right at resistance. If it gets through here, we’re looking at 16 and 18 going forward on BBBY.
3. California Resources (NYSE:CRC) popped on Wednesday as oil turned around. It ran up another 1.09, or 16.54%, to 7.68, with a high of 7.89, on 4.9 million shares. I like the look of this. If it gets a little higher and takes out the 8-8 1/4 range, it might very well be back to 10 very quickly.
4. Endo International (NASDAQ:ENDP) broke out of a triple top and wedge on Wednesday, jumping 52 cents, or 10.32%, to 5.51, with a high of 5.55, on 7.1 million shares. It should accelerate here. The minimum target is 6 1/4, 6 3/4, and maybe as high as 8 on this move.
5. ImmunoGen (NASDAQ:IMGN)exploded on Wednesday after retesting. It moved up 44 cents, or 12.36%, to 4.00, with a high of 4.02, on 3.2 million shares. Volume was low.
6. Owens & Minor (NYSE:OMI) popped 36 cents, or 5.44%, to 6.98, with a high of 7.30, on 2.1 million shares, on Wednesday and I put a swing on it. It backed off. Now, I’m looking for a move to 7 1/2, which is my near-term target. If it gets through that, 8 1/2, then 10 are intermediate-term targets.
7. Pacific Gas & Electric (NYSE:PCG), on a deal with wildfire victims, made a huge pop on Wednesday, closing 95 cents, or 11%, to 9.47, with a high of 10.75, on 60 million shares, and then backed off. It did get up to the first target zone that filled the gap. Let’s see if it will extend. Targets are 12 and 13 1/2.
Stocks on the long side included Arbutus Biopharma Corporation (ABUS), Amarin Corporation plc (AMRN), Aurinia Pharmaceuticals Inc. (AUPH), Bed Bath & Beyond Inc. (NASDAQ:BBBY), Can-Fite BioPharma Ltd. (CANF), California Resources Corporation (CRC), Camping World Holdings, Inc. (CWH), Endo International plc (ENDP), Exelixis, Inc. (EXEL), Galmed Pharmaceuticals Ltd. (GLMD), GTT Communications, Inc. (GTT), ImmunoGen, Inc. (IMGN), Jounce Therapeutics, Inc. (JNCE), Kodiak Sciences Inc. (KOD), Mallinckrodt (NYSE:MNK) Public Limited Company (MNK), Owens & Minor, Inc. (OMI), PG&E Corporation (PCG), Provention Bio, Inc. (PRVB), Proteostasis Therapeutics, Inc. (PTI), Avita Medical Limited (RCEL), Renewable Energy Group, Inc. (REGI), Relmada Therapeutics, Inc. (RLMD), SeaChange International, Inc. (SEAC), Veracyte, Inc. (VCYT), Wrap Technologies, Inc. (WRTC), and Xenon Pharmaceuticals Inc. (XENE).